News Center

Home page

Peak Report

News reports

Announcement on the Subsidiary's Receipt of the Decision of the Environmental Protection Department Ordering to Stop Production and Remediation

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2018-020

Bond Abbreviation: 13 Jianfeng 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement

of the Company's Board of Directors and all directors guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents

Recently, Anhui Xinbeika Chemical Co., Ltd. (hereinafter referred to as "Anhui Beika"), a subsidiary of the company, received the Dongzhi County Environmental Protection Bureau's "Decision on Ordering Suspension of Production and Rectification" (

Donghuan Zit [2018] No. 04), the main contents are hereby announced as follows:

1. the contents of the "Decision on Ordering to Stop Production and Rectification"

(I) Investigation and Findings of Environmental Violations

After investigation by our bureau, it is found that your company has implemented the following environmental violations: "Your company's annual output of 500

tons of acetamiprid is in production, and the valve of the gas outlet pipeline of the activated carbon adsorption tank of the waste gas treatment facility in the 201 workshop is closed, the waste gas in the tank overflows from the outlet of the sewage pipe and the inlet and outlet of activated carbon replacement, etc., and the smell on site is heavy." The above facts of

are based on evidence such as the on-site (survey) record, investigation and inquiry record, on-site photos and so on on June 22, 2018

by our bureau.

The above actions of your company violate the provisions of Article 20, paragraph 2, of the the People's Republic of China Air Pollution Prevention and Control Law.

The basis and type of the (II)'s decision to suspend production for rectification

According to Item (III) of Paragraph 1 of Article 99 of the the People's Republic of China Air Pollution Prevention and Control Law, and Item (I) of Article 6 of the Measures for the Implementation of Restrictions on Production and Suspension of Production by Environmental Protection Authorities, our bureau has decided to order your company to implement suspension of production for rectification.

Implementation method and deadline for (III) shutdown rectification

, your company shall immediately stop production from the date of receipt of this decision, and take corrective measures to formulate and implement the rectification plan.

. Your company shall report the rectification plan to our bureau for the record and make it public within 15 working days after receiving this decision. The rectification plan shall determine the corrective measures, the progress of the project, the guarantee of funds and the responsible personnel.

. After your company completes the rectification task, it shall report the completion of the rectification task and the public disclosure of the rectification information to our bureau for the record within 15 working days.

. Your company shall not have any illegal pollutant discharge during the rectification period, and shall not resume production without reporting the completion of the rectification task to our bureau for the record.

The period of suspension of production for rectification is from the date of service of this decision to the date of cancellation of the suspension of production for rectification.

Our bureau will supervise your unit after the implementation of the shutdown rectification, and conduct follow-up inspection after the shutdown rectification is lifted. If your company refuses to carry out rectification as required or commits illegal acts after resuming production, our bureau will impose administrative penalties or administrative treatment in accordance with the law according to your company's illegal circumstances and environmental consequences.

Ways and Time Limit for (IV) to Apply for Administrative Reconsideration or File Administrative Litigation

If your company does not accept this decision, it may apply for administrative reconsideration to Chizhou Municipal Environmental Protection Bureau or Dongzhi County People's Government within 60 days from the date of receipt of this decision in accordance with the provisions of Article 9 of the the People's Republic of China Administrative Reconsideration Law, an administrative lawsuit may also be brought to the people's Court of Dongzhi County within six months from the date of receipt of this decision in accordance with Article 46 of the the People's Republic of China Administrative procedure Law. If an application for administrative reconsideration or an administrative lawsuit is filed, the implementation of this decision shall not be suspended.

If you do not apply for administrative reconsideration, file an administrative lawsuit, or perform this decision within the time limit, our bureau will apply to the people's court for enforcement in accordance with the law.

2. Rectification Measures

Company attached great importance to the above decision and immediately requested Anhui Beika to actively cooperate with the environmental protection department in inspection and stop illegal acts. The specific measures are as follows:

. In response to the incident, the company instructed Jianfeng Pharmaceutical to immediately set up an environmental protection incident emergency working group to investigate the incident and supervise the rectification; at the same time, arrange the company's production enterprises to conduct a comprehensive environmental self-examination to prevent the occurrence of similar incidents.

, prepare a rectification plan and arrange special funds to further upgrade the existing waste gas treatment system in Beika, Anhui Province.

. During the period of shutdown and rectification, Anhui North Carolina will be arranged to carry out annual routine equipment maintenance to ensure the normal operation of production facilities after resumption of production.

Anhui North Carolina will complete the rectification as soon as possible and report the completion of the rectification to the Environmental Protection Bureau, so as to resume normal production as soon as possible.

Impact of 3. on the Company

2018

In January and August, the board of directors of the company approved that the subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. acquired 55% of the equity of Shanghai Beika Pharmaceutical Technology Co., Ltd. by acquiring shares and increasing capital. Anhui Beika is a wholly-owned subsidiary of Shanghai Beika Pharmaceutical Technology Co., Ltd. In May 2018, the industrial and commercial change registration and handover procedures for the investment were completed. In accordance with the "Application Guide to Enterprise Accounting Standards No. 20-Business Combinations", the Company has included Shanghai Beika Pharmaceutical Technology Co., Ltd. and its subsidiaries in the scope of the Company's consolidation since June 2018.

At the end of 2017

, the company's total assets were 41.76 .1 billion yuan, and the net assets attributable to the owners of the parent company were 2.627 billion yuan. In 2017, the company realized operating income of 2.827 billion yuan and realized net profit attributable to the owners of the parent company. 0.348 billion yuan. At the end of 2017, Anhui North Card's total assets were 0.047 billion yuan and net assets were 0.012 billion yuan. Anhui North Card's annual operating income in 2017 was 0.046 billion yuan and net profit was -0.008 billion yuan. Anhui North Card's total assets were about 1.13 of the company's total assets and its operating income was about 1.63 of the company's operating income. Anhui North Card has a small impact on the Company's overall operating income and efficiency.

The company will strictly follow the "Shanghai Stock Exchange Stock Listing Rules" and other relevant requirements to do a good job of information disclosure in a timely manner. Please invest rationally and pay attention to investment risks.

This is to announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

July 5, 2018

More information

A hard work, a harvest

2020

11-03

Natural Products Company Sends Staff to Participate in Fine Regulation Training

2020

11-03

Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better

On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)

2020

10-23

Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"

On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)

2020

10-09

The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center

News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)

2020

09-22

Spike Pharmaceutical Added New Products

On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)

2020

09-11

< 1...18 19 20...61 > 跳转到页